- Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
-
Hui KY, Fung J, Cheung KS, Mak LY, Seto WK, Yuen MF
- KMID: 2540416
- Gut Liver.
- 2023 Mar;17(2):280-287.
- doi: 10.5009/gnl220122
Background/Aims: Hepatitis B surface antigen (HBsAg) seroclearance remains uncommon in chronic hepatitis B (CHB) infection. During acute flares of CHB (AFOCHB), alanine aminotransferase elevation reflects a mounting immune response toward... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas
-
Lan TY, Lin YC, Tseng TC, Yang HC, Kao JH, Cheng CF, Lee TJ, Huang SC, Lu CH, Li KJ, Hsieh SC
- KMID: 2540417
- Gut Liver.
- 2023 Mar;17(2):288-298.
- doi: 10.5009/gnl210551
Background/Aims: Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in... -
- CITED
-
- Close
- SHARE
-
- Close
- Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
-
Lan MY, Lin HCL, Hu TH, Chen SFC, Chen CH, Chang YY, Chiu KW, Lin TK, Chen SS
- KMID: 2537184
- J Clin Neurol.
- 2023 Jan;19(1):52-59.
- doi: 10.3988/jcn.2023.19.1.52
Background and Purpose Oral nucleos(t)ide analogs (NAs) are the mainstay treatment for chronic hepatitis B (CHB). Myotoxicity is an important extrahepatic effect related to NA treatment. Telbivudine is the NA... -
- CITED
-
- Close
- SHARE
-
- Close
- New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
-
Lim YS
- KMID: 2538208
- Clin Mol Hepatol.
- 2023 Jan;29(1):118-119.
- doi: 10.3350/cmh.2022.0413
-
- CITED
-
- Close
- SHARE
-
- Close
- Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
-
Liang LY, Wong VWS, Wong GLH, Yip TCF
- KMID: 2538207
- Clin Mol Hepatol.
- 2023 Jan;29(1):113-117.
- doi: 10.3350/cmh.2022.0333
-
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
-
Mak LY, Wong D, Kuchta A, Hilfiker M, Hamilton A, Chow N, Mao X, Seto WK, Yuen MF
- KMID: 2538211
- Clin Mol Hepatol.
- 2023 Jan;29(1):146-162.
- doi: 10.3350/cmh.2022.0172
Background/Aims: We investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of... -
- CITED
-
- Close
- SHARE
-
- Close
- Report on the External Quality Assessment Scheme for Molecular Microbiology, Hepatitis Virus 1, 2 (2016–2021)
-
Moon HW, Lee TH, Seo JD
- KMID: 2538677
- Lab Med Qual Assur.
- 2022 Dec;44(4):191-198.
- doi: 10.15263/jlmqa.2022.44.4.191
The clinical demand for molecular tests is increasing and thus, the need for quality control is also increasing. The Korean Association of External Quality Assessment Service has operated a test... -
- CITED
-
- Close
- SHARE
-
- Close
- Validity and Reliability of Translated Version of the Chronic Hepatitis B Self-Management Scale
-
Kim EV, Oh H
- KMID: 2537647
- Korean J Adult Nurs.
- 2022 Dec;34(6):555-564.
- doi: 10.7475/kjan.2022.34.6.555
Purpose This study aimed to evaluate the validity and reliability of the revised Korean version of the Chronic Hepatitis B Self-Management Scale-K16 (CHBSMS-K16). Methods Using the convenience sampling method, the data of chronic... -
- CITED
-
- Close
- SHARE
-
- Close
- Updated Treatment Guidelines for Chronic Hepatitis B
-
An J
- KMID: 2536632
- Korean J Med.
- 2022 Dec;97(6):353-360.
- doi: 10.3904/kjm.2022.97.6.353
Chronic hepatitis B virus (HBV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma in Korea. While the prevalence of HBV infection is gradually declining in Korea, 3... -
- CITED
-
- Close
- SHARE
-
- Close
- Liver Diseases in South Korea: A Pulse Check of the Public’s Knowledge, Awareness, and Behaviors
-
Lee HW, Kim M, Youn J, Singh S, Ahn SH
- KMID: 2536358
- Yonsei Med J.
- 2022 Dec;63(12):1088-1098.
- doi: 10.3349/ymj.2022.0332
Purpose: National surveys in Korea have spotlighted suboptimal levels of awareness among the public towards liver-related health and diseases, leading to progressive reform of national policies and education efforts. This... -
- CITED
-
- Close
- SHARE
-
- Close
- Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus
-
Wu D, Rao Q, Xie Z, Zhu X, Che Y, Wu J, Gao H, Zhang J, Hou Z, Cheng X, Sun Z
- KMID: 2534354
- Clin Mol Hepatol.
- 2022 Oct;28(4):912-925.
- doi: 10.3350/cmh.2022.0121
Background/Aims: Acute-on-chronic liver failure (ACLF) is a catastrophic illness. Few studies investigated the prognostic value of vitamin D-binding protein (VDBP) for hepatitis B virus (HBV)-related ACLF (HBV-ACLF) resulted in conflicting... -
- CITED
-
- Close
- SHARE
-
- Close
- COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis
-
Cheung KS, Mok CH, Mao X, Zhang R, Hung IF, Seto WK, Yuen MF
- KMID: 2534353
- Clin Mol Hepatol.
- 2022 Oct;28(4):890-911.
- doi: 10.3350/cmh.2022.0087
Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study
-
Mishra A, Puri AS, Sachdeva S, Dalal A
- KMID: 2535818
- Intest Res.
- 2022 Oct;20(4):445-451.
- doi: 10.5217/ir.2021.00106
Background/Aims: Response to vaccine in patients with inflammatory bowel disease is lower than in the general population. We aimed to evaluate the efficacy of hepatitis B virus (HBV) vaccination in... -
- CITED
-
- Close
- SHARE
-
- Close
- Lactic Acidosis Adverse Drug Reaction Reporting Aspect Evaluation of Hepatitis B Treatment Using Korea Adverse Event Reporting System
-
Lee S, Kwon M, Lee S, Kim J
- KMID: 2534685
- .
- 2022 Sep;14(2):144-148.
- doi: 10.56142/jperm.22.0012
Chronic hepatitis B is caused by the hepatitis B virus and is known as a major cause of chronic liver disease with a high worldwide prevelance. And it has a... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Human Immunodeficiency Virus/Hepatitis B Virus Coinfection with Persistent Anorexia and Weight Loss as Early Clinical Symptom
-
Lee SH, Lee JG
- KMID: 2533242
- Korean J Fam Pract.
- 2022 Sep;12(4):280-283.
- doi: 10.21215/kjfp.2022.12.4.280
Human immunodeficiency virus (HIV) infection has a very low prevalence among South Koreans and exhibits nonspecific symptoms such as fever and loss of appetite in the early stages of infection.... -
- CITED
-
- Close
- SHARE
-
- Close
- Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea
-
Song BG, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW
- KMID: 2533150
- Korean J Intern Med.
- 2022 Sep;37(5):1082-1087.
- doi: 10.3904/kjim.2021.452
Changes in the prevalence of disease over time provide valuable information from a public health perspective. We used data from Korea Military Manpower Administration medical examinations for conscription between 2003... -
- CITED
-
- Close
- SHARE
-
- Close
- Viral Hepatitis in Patients with Inflammatory Bowel Disease
-
Shin SH, Park SH
- KMID: 2532678
- Korean J Gastroenterol.
- 2022 Aug;80(2):51-59.
- doi: 10.4166/kjg.2022.096
There has been a rise in the incidence of inflammatory bowel disease (IBD) in developing countries, including South Korea. Consequently, the use of immunosuppressive agents such as immunomodulators or biologics... -
- CITED
-
- Close
- SHARE
-
- Close
- RNA interference as a novel treatment strategy for chronic hepatitis B infection
-
Hui RWH, Mak LY, Seto WK, Yuen MF
- KMID: 2531368
- Clin Mol Hepatol.
- 2022 Jul;28(3):408-424.
- doi: 10.3350/cmh.2022.0012
Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
-
Ahn SM, Choi J, Ye BD, Yang SK, Oh JS, Kim Y, Lee C, Yoo B, Park SH, Hong S
- KMID: 2531239
- Gut Liver.
- 2022 Jul;16(4):567-574.
- doi: 10.5009/gnl210204
Background/Aims: Anti-hepatitis B virus (HBV) therapy is required for patients with HBV infection receiving biologics because of the high risk of HBV reactivation. However, it is unclear when to start... -
- CITED
-
- Close
- SHARE
-
- Close
- The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection
-
Yu JH, Cho SG, Jin YJ, Lee JW
- KMID: 2531364
- Clin Mol Hepatol.
- 2022 Jul;28(3):351-361.
- doi: 10.3350/cmh.2021.0281
Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral... -
- CITED
-
- Close
- SHARE
-
- Close
